A. D. Burden

Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis

Y. Lau, A. D. Burden, 2023, Expert review of clinical immunology.

Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial

M. Lebwohl, T. Tsai, D. Thaçi, 2023, The Lancet.

Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterisation of Flare Treatment in EFFISAYIL® 1.

S. Choon, C. Thoma, S. Visvanathan, 2024, The Journal of investigative dermatology.

International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis From the International Psoriasis Council.

F. Capon, A. M. Affandi, S. Marrakchi, 2024, JAMA dermatology.